Summary
Becton, Dickinson and Company (BD) announced significant leadership changes within its executive team through an 8-K filing on August 25, 2022. These changes involve the appointment of two new Segment Presidents and the departure of one existing executive. Specifically, Michael Garrison has been appointed Executive Vice President and President of the Medical Segment, and Richard Byrd has been appointed Executive Vice President and President of the Interventional Segment, both effective September 6, 2022. These appointments are aimed at strengthening leadership within key operational areas of the company. Concurrently, Simon Campion, who previously served as the Executive Vice President and President of the Medical Segment, will be departing BD on September 9, 2022, to pursue another opportunity in the healthcare industry. Mr. Campion's departure follows BD's acquisition of C.R. Bard, Inc. Investors should monitor how these leadership transitions impact the strategic direction and operational performance of the Medical and Interventional segments.
Key Highlights
- 1Appointment of Michael Garrison as EVP and President, Medical Segment, effective September 6, 2022.
- 2Appointment of Richard Byrd as EVP and President, Interventional Segment, effective September 6, 2022.
- 3Departure of Simon Campion, former EVP and President, Medical Segment, effective September 9, 2022.
- 4Mr. Campion joined BD through the acquisition of C.R. Bard, Inc.
- 5The company issued a press release on August 25, 2022, detailing these leadership changes.
- 6These executive changes are effective in early September 2022.